VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
reAlpha Tech Corp. vs AstraZeneca PLC
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
reAlpha Tech Corp.
AIRE · Nasdaq Capital Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into reAlpha Tech Corp.'s moat claims, evidence, and risks.
View AIRE analysisAstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisComparison highlights
- Moat score gap: AstraZeneca PLC leads (71 / 100 vs 42 / 100 for reAlpha Tech Corp.).
- Segment focus: reAlpha Tech Corp. has 2 segments (83.5% in Homebuying Platform & Transaction Services); AstraZeneca PLC has 6 segments (41% in Oncology).
- Primary market structure: Competitive vs Oligopoly. Pricing power: Weak vs Strong.
- Moat breadth: reAlpha Tech Corp. has 4 moat types across 2 domains; AstraZeneca PLC has 4 across 3.
Primary market context
reAlpha Tech Corp.
Homebuying Platform & Transaction Services
Integrated U.S. residential real estate transaction services platform (brokerage + mortgage + title)
United States
Homebuyers
Transaction intermediary / service provider
83.5%
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Side-by-side metrics
Moat coverage
Shared moat types
No overlap yet.
reAlpha Tech Corp. strengths
AstraZeneca PLC strengths
Segment mix
reAlpha Tech Corp. segments
Full profile >Homebuying Platform & Transaction Services
Competitive
AiChat Conversational AI SaaS
Competitive
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.